Skip to content

PP&E (Net) at other companies

Mannkind logo
MannkindMNKD
$82.55M-1.5%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$1.99M-22.9%
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
$13.5M+6.9%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$3.4M-6.0%
Kiniksa Pharmaceuticals International, plc logo
Kiniksa Pharmaceuticals International, plcKNSA
$1.99M+228%
Cytokinetics logo
CytokineticsCYTK
$82.44M+22.7%

Other financials

Income statement

See full
Operating income-$45.3M-2.0%
Net income-$39.3M+6.8%
EPS (diluted)-$0.47+40.5%

Balance sheet

See full
Cash & equivalents$1.2M-14.6%
Total equity$638.1M+86.8%
Total assets$652.9M+83.9%

Cash flow

See full
Operating cash flow-$39.5M+13.2%
CapEx$15.0K
Free cash flow-$37.9M+43.3%

Valuation

See full
Market cap$2.27B+124%

Returns & leverage

See full
Return on equity-31%-9.6pp
Current ratio44.3×+17.8×

Where this comes from

Reported directly by Mineralys Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Mineralys Therapeutics, Inc.'s pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Mineralys Therapeutics, Inc.'s PP&E (net)?
Mineralys Therapeutics, Inc. (MLYS) reported PP&E (net) of $32K in Q1 2026.
How has Mineralys Therapeutics, Inc.'s PP&E (net) changed year-over-year?
Mineralys Therapeutics, Inc.'s PP&E (net) decreased by 15.8% year-over-year, from $38K to $32K.
What does PP&E (net) mean?
Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.